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Summary. Background and aim of the work: The Lynch Syndrome (LS) is associated with germline mutations 
in one of the MisMatch Repair (MMR) genes. Most of germline mutations are point variants, followed by 
large rearrangements that account to 15-55% of all pathogenic mutations. Many study reporting the frequen-
cy of large rearrangements in the MLH1 and MSH2 genes were performed, while, little is known about the 
contribution of large rearrangements in other MMR genes, as PMS2 and MSH6. Therefore, in this study we 
investigated the involvment of large rearrangements in MSH6 and PMS2 genes in a well-characterized series 
of 20 LS southern Italian patients. Methods: These large rearrangements are not usually detected by methods 
of mutation analysis, such as denaturing high-performance liquid chromatography (DHPLC) and direct 
DNA sequencing, but they are detectable by a known technique as the Multiplex Ligation-Probe Depend-
ent Amplification (MLPA) assay. Results: No large rearrangements were identified in MSH6 gene; instead, 
a large rearrangement was identified in PMS2 gene. A large duplication including the exons 3 and 4 of the 
PMS2 gene was identified in a patient who developed a rectum carcinoma at 45 years of age, an endometrial 
carcinoma and a vaginal cancer at the 65 years of age. Conclusion: We can affirm that the detection of large 
rearrangements in the MSH6 and PMS2 genes should be included in the routine testing for Lynch syndrome, 
especially considering the simplicity of the MLPA assay.
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Clinical case report
Introduction
The main hereditary gastrointestinal cancer syn-
dromes (1) include the Familial Polyposis Adenoma-
tous (2, 3), PTEN Hamartoma Tumor Syndrome (4), 
Peutz Jeghers (5) and Lynch Syndrome (6). Mutations 
in MisMatch Repair (MMR) genes are responsible for 
the early onset of colorectal cancer in Lynch syndrome 
(LS) (6). Germline mutations in MLH1, MSH2 and 
MSH6 genes account to 70-80% of LS cases, while a 
minor contribution (about 10-30%) is given by mu-
tations in the PMS2, MLH3 and MSH3 genes (7-9). 
The mutations are distributed heterogeneously along 
each MMR gene, denoting the absence of “hot spots” 
mutations. Regarding to nature of germline mutations, 
most of these are point variants, followed by large re-
arrangements that account to 15-55% of all patho-
genic mutations (10). Such alterations are mainly due 
to the presence of highly repeated sequences such as 
Alu sequences, which driver the recombination pro-
cesses (11). A higher percentage of these rearrange-
ments (deletions or duplications) are present in MSH2 
gene (20%) (12, 13); also in MLH1, MSH6 and PMS2 
genes several large rearrangements were described in 
international literature (14). Molecular screening in 
suspected LS families attempted to find relationships 
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between a particular phenotype and a mutation in one 
of MMR gene (15). Although, the correlation geno-
type-phenotype for LS was not clarified to date (16), it 
is possible to affirm that the classic forms of LS, char-
acterized by a early onset age of tumor (about 42 years) 
high penetrance and high degree of microsatellite in-
stability (MSI) (17) were associated with point muta-
tions in MSH2 and MLH1 genes. While, MSH6 point 
mutations were reported in the literature as causing an 
“attenuated” forms of LS, with a later onset of tumor 
(18). Finally, point mutations in the PMS2 gene were 
reported to cause early onset of tumors, that showed 
microsatellite instability but with different somatic 
features (19). Instead, the large rearrangements in 
any MMR genes (MLH1, MSH2, MSH6 and PMS2) 
cause a similar clinical phenotype of disease, that is 
corresponding to classic forms of LS (20). These large 
rearrangements are not usually detected by methods 
of mutation analysis, such as denaturing high-perfor-
mance liquid chromatography (DHPLC) and direct 
DNA sequencing, but they are detectable by a known 
technique as the Multiplex Ligation-Probe Dependent 
Amplification (MLPA) (12) assay. So far, many large 
rearrangements in the MLH1 and MSH2 genes were 
described as responsible of Lynch syndrome pheno-
type, while, little is known about the identification of 
large rearrangements in other MMR genes, as PMS2 
and MSH6. In this study we researched the large re-
arrangements in MSH6 and PMS2 genes in a well-
characterized series of 20 LS southern Italian patients 
already negative for point mutations in the MLH1, 
MSH2, MSH6, PMS2 and MLH3 genes and for large 
rearrangements in the MLH1 and MSH2 genes. Iden-
tification of mutation responsible to LS phenotype, it 
is important in order to not exclude from the preven-
tion and treatment program the subjects at risk of de-
veloping an early colon cancer.
Case report
In this study, the DNA of 20 selected subjects 
were analyzed by MLPA analysis to detection of large 
rearrangements in two MMR genes, MSH6 and PMS2 
genes. These twenty subjects of Italian origin, 12 se-
lected by the diagnostic criteria of Amsterdam (21) 
and 8 by the Bethesda guidelines (according to MSI 
high status) (22, 23) were recruited from several health 
centers in Southern Italy. Furthermore, as negative 
controls we collected 7 healthy samples from Clinical 
Department of Laboratory Medicine of our Hospital 
(Federico II of Naples). All patients received genetic 
counseling and gave their written informed consent to 
participate in this study. The detection of large genom-
ic rearrangements in MSH6 and PMS2 in our selected 
patients was performed on genomic DNA using the 
SALSA MLPA P008-B1 PMS2 kit -Lot B1-0112 
and P072-C1 MSH6 kit (MRC-Holland, Nether-
lands) according to the manufacturer’s instructions. 
No large rearrangements were identified in MSH6 
gene; instead, a large rearrangements was identified in 
PMS2 gene. A large duplication including the exons 
3 and 4 of the PMS2 gene was identified in a sub-
ject (our number 1363) who developed a rectum car-
cinoma at 45 years of age, an endometrial carcinoma 
and a vaginal cancer at the 65 years of age. Figure 1A. 
For all patients, MLPA results were confirmed in three 
independent experiments. For the subject with our 
number 1363 and 7 negative references, we performed 
other two MLPA experiments using a 4 fold reduced 
amount of Ligase65 enzyme (0.25 µl/reaction), as sug-
gested data sheet of P008-B1 PMS2 kit, Fig. 1B.
Discussions
Twenty subjects belonging to families with clinical 
diagnosis of LS were selected for this study. Of these 
twenty families, twelve meet the criteria of Amsterdam 
and eight showing an atypical phenotype were selected 
by MSI status on DNA extracted from tumoral tissue 
(data not shown). We performed the detection of large 
rearrangements in MSH6 and PMS2 genes in these LS 
families already negative for point mutations in MLH1, 
MSH2, MSH6, PMS2 and MLH3 genes and for large 
rearrangements in MLH1 and MSH2. Therefore, in 
order to not exclude from the prevention and treat-
ment program these subjects at risk of developing an 
early colon cancer we extended the research of muta-
tion to analysis of large rearrangements in MSH6 and 
PMS2 genes that not are usually analyzed in genetic 
testing for LS. However, large rearrangements in these 
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Figure 1. A. Family pedigree of our patient 1363 with a large duplication in PMS2 gene. Symbols and abbreviations used are denoted 
as fellow: arrows, index case; black symbol, colorectal cancer or tumors associate with LS; Co, colon cancer; End, endometrial cancer; 
Vag, vaginal cancer. Number next to diagnosis denote age at onset. and B. Electropherogram and graphical analysis showing the large 
duplication including 3 and 4  exons of PMS2 gene.
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genes were reported in literature (14, 24). In this study, 
no large rearrangements were identified in MSH6 gene 
among our LS subjects. Instead, we identified a likely 
duplication including the exons 3 and 4 of PMS2 gene. 
This duplication was identified in our LS patient (n. 
1363) that developed a rectal carcinoma at the age of 
45 and later a uterine and vaginal carcinoma at the age 
of 65, Fig. 1A. Literature data indicate that monoal-
lelic mutations in PMS2 gene are responsible of LS 
phenotype characterized by the presence of multiple 
tumors (25). The low penetrance could be to explain 
by redundant function of PMS2 protein in the MMR 
complex. This could explain the absence of a significant 
family history for the subject 1363. Unfortunately, due 
to limited availability of subjects 1363 and to difficulty 
of analyzing the PMS2 gene (26) we were not able to 
performed other experiments to confirm the MLPA 
result. However, as suggested data sheet of SALSA 
MLPA PMS2 kit P008-B1 to confirm the obtained 
result we repeated the MLPA experiment using a 4 
fold reduced amount of Ligase65 enzyme, to exclude 
that this duplication of 3 and 4 exons of PMS2 could 
be an artifact of MLPA reaction (Fig. 1B). This condi-
tion could to occur due to difficulty of analyzing the 
PMS2 gene also by MLPA reaction for the presence of 
numerous pseudogenes (27). In conclusion, we believe 
that are needed further molecular analysis to confirm 
the duplication identified in PMS2 gene. However, we 
can affirm that the detection of large rearrangements in 
the MSH6 and PMS2 genes should be included in the 
routine testing for Lynch syndrome, especially consid-
ering the simplicity of the MLPA assay. Finally, this 
study reaffirms the importance to identify pathogenic 
mutations in LS families to facilitate pre-symptomatic 
diagnosis and to improve therapeutic pathway in order 
to promote a personalized medicine (28).
References
  1.  De Rosa M, Pace U, Rega D, et al. Genetics, diagnosis 
and management of colorectal cancer (Review). Oncol Rep 
2015; 34(3): 1087-96.
  2.  Dodaro C, Grifasi C, Florio J, et al. The role of mutation 
analysis of the APC gene in the management of FAP pa-
tients. A controversial issue. Ann Ital Chir 2016; 87: 321-5.
  3.  De Rosa M, Galatola M, Borriello S, et al. Implication of 
adenomatous polyposis coli and MUTYH mutations in fa-
milial colorectal polyposis. Dis Colon Rectum 2009; 52(2): 
268-74.
  4.  Paparo L, Rossi GB, Delrio P, et al. Differential expression 
of PTEN gene correlates with phenotypic heterogeneity in 
three cases of patients showing clinical manifestations of 
PTEN hamartoma tumour syndrome. Hered Cancer Clin 
Pract 2013; 25; 11(1): 8. 
  5.  Meserve EE, Nucci MR. Peutz-Jeghers Syndrome: Pathobi-
ology, Pathologic Manifestations, and Suggestions for Rec-
ommending Genetic Testing in Pathology Reports. Surg 
Pathol Clin 2016; 9(2): 243-68. 
  6.  Liccardo R, De Rosa M, Izzo P, Duraturo F. Novel implica-
tions in molecular diagnosis of lynch syndrome Gastroen-
terol Res Pract 2017; 2017: 2595098. 
  7.  Peltomäki P. Update on Lynch syndrome genomics. Fam 
Cancer 2016; 15(3): 385-93. 
  8.  Duraturo F, Liccardo R, Izzo P. Coexistence of MLH3 ger-
mline variants in colon cancer patients belonging to families 
with Lynch syndrome-associated brain tumors. J Neuroon-
col 2016; 129(3): 577-8. 
  9.  Duraturo F, Liccardo R, Cavallo A, et al. Association of 
low-risk MSH3 and MSH2 variant alleles with Lynch syn-
drome: probability of synergistic effects. Int J Cancer 2011; 
129(7): 1643-50.
10.  InSiGHT (The International Society for Gastrointesti-
nal Hereditary Tumours Incorporated) 1985. http://www.
insight-group.org/ 
11.  Sen SK, Han K, Wang J, et al. Human genomic deletions 
mediated by recombination between Alu elements. Am J 
Hum Genet 2006; 79(1): 41-53.
12.  Duraturo F, Cavallo A, Liccardo R, et al. Contribution of 
large genomic rearrangements in Italian Lynch syndrome 
patients: characterization of a novel alu-mediated deletion. 
Biomed Res Int 2013; 2013: 219897.
13.  Liccardo R, De Rosa M, Rossi GB, et al. Characterization 
of novel, large duplications in the MSH2 gene of three un-
related Lynch syndrome patients. Cancer Genetics 2018, 
221: 19-24 
14.  van der Klift H, Wijnen J, Wagner A, et al. Molecular char-
acterization of the spectrum of genomic deletions in the 
mismatch repair genes MSH2, MLH1, MSH6, and PMS2 
responsible for hereditary nonpolyposis colorectal cancer 
(HNPCC). Genes Chromosomes Cancer 2005; 44(2): 123-
38.
15.  Lynch HT, Lanspa S, Shaw T, et al. Phenotypic and geno-
typic heterogeneity of Lynch syndrome: a complex diagnos-
tic challenge. Fam Cancer 2017 Oct 25.
16.  Liccardo R, De Rosa M, Duraturo F. Same MSH2 Gene 
Mutation But Variable Phenotypes in 2 Families With 
Lynch Syndrome: Two Case Reports and Review of Geno-
type-Phenotype Correlation. Clin Med Insights Case Rep 
2018 Jan 23; 11: 1179547617753943.
17.  Yamamoto H, Imai K. Microsatellite instability: an update. 
Arch Toxicol 2015; 89(6): 899-921.
18.  Liccardo R, De Rosa M, Rossi GB, et al. Incomplete Seg-
Large rearrangements in MSH6 and PMS2 genes 51
regation of MSH6 Frameshift Variants with Phenotype of 
Lynch Syndrome. Int J Mol Sci 2017; 18(5). 
19.  Li L, Hamel N, Baker K, et al. A homozygous PMS2 
founder mutation with an attenuated constitutional mis-
match repair deficiency phenotype. J Med Genet 2015; 
52(5): 348-52. 
20.  Smith MJ, Urquhart JE, Harkness EF, et al. The Contribu-
tion of Whole Gene Deletions and Large Rearrangements 
to the Mutation Spectrum in Inherited Tumor Predisposing 
Syndromes. Hum Mutat 2016; 37(3): 250-6.
21.  Park JG1, Vasen HF, Park KJ, et al. Suspected hereditary 
nonpolyposis colorectal cancer: International Collaborative 
Group on Hereditary Non-Polyposis Colorectal Cancer 
(ICG-HNPCC) criteria and results of genetic diagnosis. 
Dis Colon Rectum 1999; 42(6): 710-5.
22.  Boland CR1, Thibodeau SN, Hamilton SR, et al. A Nation-
al Cancer Institute Workshop on Microsatellite Instability 
for cancer detection and familial predisposition: develop-
ment of international criteria for the determination of mi-
crosatellite instability in colorectal cancer. Cancer Res 1998 
15; 58(22): 5248-57.
23.  Duraturo F, Liccardo R, Cavallo A, et al. Multivariate anal-
ysis as a method for evaluating the pathogenicity of novel 
genetic MLH1 variants in patients with colorectal cancer 
and microsatellite instability. Int J Mol Med 2015; 36(2): 
511-7. 
24.  Brea-Fernández AJ, Cameselle-Teijeiro JM, Alenda C, et 
al. High incidence of large deletions in the PMS2 gene in 
Spanish Lynch syndrome families. Clin Genet 2014; 85(6): 
583-8. doi: 10.1111/cge.12232. Epub 2013 Jul 28.
25.  De Rosa M, Fasano C, Panariello L, et al. Evidence for a 
recessive inheritance of Turcot’s syndrome caused by com-
pound heterozygous mutations within the PMS2 gene. On-
cogene 2000; 19(13): 1719-23.
26.  Wimmer, Wernstedt A. PMS2 gene mutational analysis: di-
rect cDNA sequencing to circumvent pseudogene interfer-
ence. Methods Mol Biol 2014; 1167: 289-302.
27.  Wernstedt A, Vatorta E, Armelao F, et al. Improved multi-
ple ligation-dependent probe amplification analysis identi-
fies a deleterious PMS2 allele generated by recombination 
with crossover between PMS2 and PMS2CL. Genes Chro-
mosomes Cancer 2012; 51(9): 819-31.
28.  De Rosa M, Rega D, Costabile V, et al. The biological com-
plexity of colorectal cancer: insights into biomarkers for 
early detection and personalized care. Therap Adv Gastro-
enterol 2016; 9(6): 861-86. 
Correspondence
Francesca Duraturo, PhD 
Department of Molecular Medicine and 
Medical Biotechnology University of Naples “Federico II”,
Via Pansini, 5 80131, Naples, Italy 
Tel. +390817463136
E-mail: duraturo@dbbm.unina.it or francesca.duraturo@unina.it
